Conjunctival tumor

disease
On this page

Also known as conjunctiva neoplasmconjunctiva neoplasm (disease)conjunctiva tumorconjunctiva tumourconjunctival neoplasmconjunctival neoplasmsneoplasm of conjunctivaneoplasm of the conjunctivatumor of conjunctivatumor of the conjunctivatumour of conjunctivatumour of the conjunctiva

Summary

Conjunctival tumor (MONDO:0020204) is a cancer and 3 clinical trials. Top therapeutic interventions include ranibizumab. A subtype of conjunctival disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameconjunctival tumor
Mondo IDMONDO:0020204
Orphanet98616
NCITC2961
UMLSC0009761
MedGen3208
Anatomy (UBERON)UBERON:0001811
Is cancer (heuristic)yes

Also known as: conjunctiva neoplasm · conjunctiva neoplasm (disease) · conjunctiva tumor · conjunctiva tumour · conjunctival neoplasm · conjunctival neoplasms · conjunctival tumor · neoplasm of conjunctiva · neoplasm of the conjunctiva · tumor of conjunctiva · tumor of the conjunctiva · tumour of conjunctiva · tumour of the conjunctiva

Disease family

This is a subtype of conjunctival disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye adnexa disorderconjunctival disorderconjunctival tumor

Related subtypes (7): conjunctival degeneration, conjunctival vascular disorder, conjunctival deposit, ocular hyperemia, conjunctivochalasis, conjunctivitis, ligneous conjunctivitis

Subtypes (3): conjunctival intraepithelial neoplasm, conjunctival cancer, benign conjunctival neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified2
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00456495PHASE1COMPLETEDEffect of Ranibizumab on Malignant Conjunctival Neoplasia
NCT03515954Not specifiedCOMPLETEDAS-OCT Guided Treatment of Diffuse CSCC
NCT05645341Not specifiedCOMPLETEDArtificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
RANIBIZUMAB41